Navigation Links
Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines

MADISON, N.J. and WORCESTER, Mass., March 18, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.

Dementia is characterized by the presence of cognitive dysfunctions, such as memory loss and impaired judgment. The new test may help primary care physicians evaluate a patient presenting with cognitive impairment for potentially reversible causes of dementia, such as vitamin B12 deficiency, hypothyroidism, anemia and diabetes, based on results of biological lab tests. Patients with abnormal results may respond to treatment administered by a primary care physician to reverse the underlying cause of dementia. Patients with normal results may require evaluation by a neurologist for additional possible causes of dementia, including Alzheimer's disease.

The new panel of tests are modeled after the recommendations of the American Academy of Neurology, the American Geriatrics Association, a National Institutes of Health Consensus Panel and the European Federation of Neurological Societies.

"The evaluation of suspected dementia is a significant medical challenge because many different conditions, from low TSH levels to diabetes, can cause cognitive impairment," said Joseph J. Higgins , MD, FAAN, medical director for Quest Diagnostics Neurology and Athena Diagnostics.  "Our new test panel provides a standard laboratory evaluation to rule out confounders of memory or reversible causes of memory loss. Test results are useful in excluding co-morbidities and revealing potential risk factors, origin of confusional states and, sometimes, in identifying the primary cause of dementia."

Athena Diagnostics is a leader in dementia diagnostics primarily for neurologists, with a menu that includes eleven testing services, including cerebrospinal fluid (CSF) biomarker analysis, to aid the detection of frontotemporal dementia and other forms of dementia, including Alzheimer's disease.

Quest Diagnostics acquired Athena Diagnostics in April 2011 in order to add neurology diagnostic information services to its business, although Athena continues to operate largely as an independent business and brand. Dementia experts at Athena Diagnostics helped to define the panel's tests and report requirements, while Quest Diagnostics' experts developed and introduced the comprehensive offering at clinical laboratories where the individual tests are performed.

"This test panel highlights the ability of Quest Diagnostics and Athena Diagnostics to introduce diagnostic innovations that conform with practice parameters and complete gaps in guideline-based medical care, which is central to our diagnostic information services strategy," said Jay G. Wohlgemuth , MD, senior vice president, science and innovation, Quest Diagnostics. "We expect it will be the first of additional diagnostic information services designed to improve neurology diagnosis to emerge from collaboration with Athena Diagnostics."

The test will be unveiled during the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 (Athena Diagnostics Booth 1413). At the conference, Athena Diagnostics will also introduce several new clinical lab-developed tests for a range of rare neurological disorders, including hereditary neuropathy and neuromuscular disease.

About Athena Diagnostics
Athena Diagnostics is a leader in diagnostic testing for neurological diseases and offers innovative tests for Alzheimer's disease, muscular dystrophy and other neuromuscular and developmental disorders. Athena, a division of Quest Diagnostics, is dedicated to providing neurologists and other physicians and specialists with insights that can improve patient health.  Athena provides the most comprehensive test menu and intellectual property portfolio for neurological, endocrine, and renal conditions through more than 400 diagnostic tests. For more information, visit

About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at or follow us at Diagnostics and

Quest, Quest Diagnostics, Athena Diagnostics and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics.

Quest Diagnostics Contacts:
Wendy Bost (Media): 973-520-2800
Dan Haemmerle (Investors): 973-520-2900

SOURCE Quest Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pancreatic Cancer Action Network Opposes Sequestration Cuts To National Institutes Of Health & Cancer Research Grants
2. Questcor Reports Fourth Quarter and Full Year 2012 Results
3. Quest Diagnostics to Sell HemoCue Business to Radiometer Medical ApS
4. Quest Diagnostics to Provide Nationwide Access to Nateras New Non-Invasive Prenatal Test
5. While Half of Facial Injectable Patients Request A Specific Product, Most Still Remain Unaware of Many Brands
6. Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
7. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
8. The Myxo File Part III, Biographical story of a Cardiologist requesting help from the President, Barack H. Obama, for her patients in Chicago
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Quest Announces Battery-Powered Mobile Wireless Surgical Video Display Solution
11. NeuroQuest Close to Validation Trial for Biomarker Platform in Diagnosis of Alzheimers
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):